Ubrogepant: First Approval.

ABSTRACT: Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (±?aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (±?aura) in adults.

SUBMITTER: Scott LJ 

PROVIDER: S-EPMC7062659 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature